<DOC>
	<DOCNO>NCT02324491</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ZGN-440 ( beloranib ) obese adult subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>An Efficacy Safety Study Beloranib Obese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Phase 2 , randomize , double-blind , placebo-controlled , parallel dose arm study 12-month randomized treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Obese BMI â‰¥30 kg/m2 Type 2 diabetes mellitus HbA1c 711 % Fasting glucose &lt; 15.5 mmol/L Treated diet exercise alone stable regimen metformin , sulfonylurea , pioglitazone , DPP4 inhibitor , GLP1 receptor agonist , SGLT2 inhibitor combination agent Female subject must surgically sterile , postmenopausal use longacting contraception , include intrauterine device use implant injectable contraceptive Current recent use insulin Severe hypoglycemia within prior 6 month Metabolic disorder genetic disorder link obesity ( e.g. , PraderWilli Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>